Macromolecular Synthesis Assay Distinguishing On-Target versus Off-Target Activity in Early Antibacterial Drug Discovery Using a

The macromolecular synthesis assay was optimized in both S. aureus and E. coli imp and used to define patterns of inhibition of DNA, RNA, protein, and cell wall biosynthesis of several drug classes. The concentration of drug required to elicit pathway inhibition differed among the antimicrobial agents tested, with inhibition detected at concentrations significantly below the minimum inhibitory concentration (MIC) for tedizolid; within 4-fold of the MIC for ciprofloxacin, cefepime, vancomycin, tetracycline, and chloramphenicol; and significantly above the MIC for rifampicin and kanamycin. In a DNA gyrase/topoisomerase IV structure-based drug design optimization program, the assay rapidly identified undesirable offtarget activity within certain chemotypes, altering the course of the program to focus on the series that maintained ontarget activity.

[1]  D. Hooper.  Mode of Action of Fluoroquinolones , 2012, Drugs.

[2]  M. Cunningham.  The role of enzymology in a structure-based drug discovery program: bacterial DNA gyrase. , 2012, Methods in molecular biology.

[3]  A. Maxwell,et al.  Exploiting bacterial DNA gyrase as a drug target: current state and perspectives , 2011, Applied Microbiology and Biotechnology.

[4]  H. Moser,et al.  Physicochemical properties of antibacterial compounds: implications for drug discovery. , 2008, Journal of medicinal chemistry.

[5]  J. Barrett,et al.  Antibiotics: where did we go wrong? , 2005, Drug discovery today.

[6]  B. Oostra,et al.  Specific stimulation of ribosomal RNA synthesis in E. coli by a protein factor , 2004, Molecular and General Genetics MGG.

[7]  P. Youngman,et al.  Antimicrobials: new solutions badly needed. , 2002, Current opinion in microbiology.

[8]  D. Hooper,et al.  Mechanisms of action and resistance of older and newer fluoroquinolones. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  K. Bush,et al.  Multiple Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-Component Systems , 1999, Antimicrobial Agents and Chemotherapy.

[10]  A. Khodursky,et al.  The Mechanism of Inhibition of Topoisomerase IV by Quinolone Antibacterials* , 1998, The Journal of Biological Chemistry.

[11]  N. Jacobus,et al.  Mechanistic studies and biological activity of bioxalomycin alpha 2, a novel antibiotic produced by Streptomyces viridodiastaticus subsp. "litoralis" LL-31F508 , 1994, Antimicrobial Agents and Chemotherapy.

[12]  H. Nikaido,et al.  Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples , 1993, Antimicrobial Agents and Chemotherapy.

[13]  G. Satta,et al.  Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032) , 1990, Antimicrobial Agents and Chemotherapy.

[14]  J. S. Daly,et al.  Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound , 1988, Antimicrobial Agents and Chemotherapy.

[15]  K. Drlica,et al.  DNA gyrase on the bacterial chromosome: possibility of two levels of action. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Smith,et al.  Nalidixic Acid: an Antibacterial Paradox , 1975, Antimicrobial Agents and Chemotherapy.

[17]  W. Wehrli,et al.  Interaction of rifamycin with bacterial RNA polymerase. , 1968, Proceedings of the National Academy of Sciences of the United States of America.